THINGS YOU SHOULD KNOW...

• It is ok to ask for a second opinion
• Be sure to get your tumor tested for known biomarkers
• There may be a clinical trial available for you
• Ask about palliative care and pulmonary rehabilitation

Did you know LUNGevity has an array of resources for you or your caregiver to help you navigate your lung cancer journey?

Visit www.LUNGevity.org to learn more.

YOUR first-class stamp allows us to put more funds toward research.

LUNGevity is a 501(c)(3) organization
FEIN# 36-4433410
CFR# 12970

May 2018

228 S. Wabash Avenue, Suite 700
Chicago, IL 60604

CHICAGO OFFICE
228 S. WABASH AVENUE, SUITE 700, CHICAGO, IL 60604
P: 312.407.6100 F: 312.464.0737

BETHESDA OFFICE
697 ARLINGTON ROAD, SUITE 352, BETHESDA, MD 20814
P: 240.454.3100 F: 240.497.0034

EMAIL: INFO@LUNGEVITY.ORG
Lung Cancer HELPLine: 844-360-LUNG
www.LUNGevity.org

Find it. Treat it. Live.
The immune system protects our body from foreign invaders and abnormal cells, including cancer cells. Sometimes, cancer cells are able to get the better of the immune system by suppressing its activity.

Immunotherapy is a treatment that strengthens the natural ability of the immune system to fight cancer. Instead of targeting the cancer cells directly, immunotherapy causes a patient’s natural immune system to selectively target and kill them.

While several types of immunotherapies are being studied for use in lung cancer, the type of immunotherapy known as checkpoint inhibitors has made the most progress. These immunotherapies work by strengthening the activity of T cells, the primary immune system cells that recognize and destroy cancer cells.

Currently, three immune checkpoint inhibitors are U.S. Food and Drug Administration (FDA)-approved for the treatment of certain groups of patients with advanced stage/metastatic non-small cell lung cancer (NSCLC), while a fourth checkpoint inhibitor is approved for patients at an earlier stage in order to reduce the risk of the lung cancer progressing.

To date, about 20% of patients respond to immune checkpoint inhibitors. Among those who do respond, the response may be long-term. Scientists are looking for ways to increase the number of people who respond to this treatment, including combining treatments and boosting the immune system.

Additional types of immunotherapies—either as single drugs or in combination with other immunotherapies, targeted therapies, or chemotherapy—are being tested in clinical trials for non-small cell lung cancer. Immunotherapies for small cell lung cancer (SCLC) are also being studied in clinical trials.

CHECK WITH YOUR DOCTOR

Clinical trials offer an important treatment option for people affected by lung cancer. Advances in immunotherapy are based on information learned from patients who are enrolled in clinical trials. Clinical trials are currently studying promising immunotherapy drugs. If you are considering participating in a clinical trial, start by asking your doctor whether there is one in your area for which you might qualify.

To learn more about:
• how the immune system works,
• how immunotherapy may boost the immune system to help fight lung cancer,
• what immunotherapy options are available, and
• whether immunotherapy might be a good treatment option for you,
visit https://LUNGevity.org/for-patients-caregivers/get-educational-materials to download a copy of the LUNGevity Immunotherapy booklet.

“It is very important for people to be active partners with their physicians in the treatment of their lung cancer. Importantly, early recognition and reporting of side effects to the care team is very important to initiating early intervention, which is known to lessen the severity of these. Immunotherapy patient education helps this happen.”

SCOTT ANTONIA, MD, PHD
Moffitt Cancer Center

I am interested in information about:
• Biomarkers
• Clinical trials
• Immunotherapy
• Lung adenocarcinoma
• Squamous cell lung cancer
• Targeted therapy
• Support services/Mentors

I am a (choose one):
___ Patient/Survivor
___ Caregiver
___ Friend or family member
___ Healthcare provider
___ Organization
___ Industry partner
___ Other

NAME
ADDRESS
CITY
STATE
ZIP
PHONE
EMAIL

Visit us on the web at: www.LUNGevity.org
or contact us directly at: info@LUNGevity.org
312.407.6100